Overall, the dual lipid-lowering therapy was associated with a significant reduction in TAV [− 4.0 mm3 (CI 95% -5.4 to − 2.6)]; I2 = 0%]. Juan Patricio Nogueira. 2016;81:1175–90. PubMed Congenital Heart Disease and Pediatric Cardiology, Invasive Cardiovascular Angiography and Intervention, Pulmonary Hypertension and Venous Thromboembolism, CardioSource Plus for Institutions and Practices, Nuclear Cardiology and Cardiac CT Meeting on Demand, Annual Scientific Session and Related Events, ACC Quality Improvement for Institutions Program, National Cardiovascular Data Registry (NCDR). The addition of a PCSK9 inhibitor to a statin regimen has been shown to further reduce LDL-C levels by 43 to 64% , and its use could increase considerably since in usual clinical practice, many patients do not reach the goals proposed by combining statins with ezetimibe . Masson, W., Lobo, M., Siniawski, D. et al. 2017;376:1713–22. CAS Cochrane Database Syst Rev. PubMed 2008;358:1431–43. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: subanalysis of PRECISE-IVUS trial. The characteristics of the studies included in the analysis can be seen in Table 1. They are useful alone or in combination with statins. Article The use of statins has been and continues today to be the cornerstone of risk management of cardiovascular disease. Article This data suggest the addition of ezetimibe or PCSK9 inhibitors to statin therapy results in significantly increased regression of TAV. Daida H, Dohi T, Fukushima Y, Ohmura H, Miyauchi K. The goal of achieving atherosclerotic plaque regression with lipid-lowering therapy: insights from IVUS trials. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. JAMA. IJC Metab Endocr. 2015;56:278–85. By using this website, you agree to our At the time of the 2013 ACC/AHA Cholesterol guidelines, the panel found no supporting evidence for the routine use of non-statin drugs in combination with statins for the reduction of ASCVD events. As combination therapy with a statin and either ezetimibe or PCSK9 inhibitors lowers LDL-C levels beyond that achieved with statin monotherapy, dual lipid-lowering treatment strategy may have additional protective cardiovascular effects . Ako J, Hibi K, Tsujita K, Hiro T, Morino Y, Kozuma K, et al. Therefore, we consider the evaluation of the impact of both drugs on the regression of atherosclerosis as a very important fact. 2013;226:178–85. Council of Epidemiology and Cardiovascular Prevention, Argentine Society of Cardiology, Azcuenaga 980, C1115AAD, Buenos Aires, Argentina, Walter Masson, Martin Lobo, Daniel Siniawski, Graciela Molinero, Gerardo Masson & Melina Huerín, Argentine Society of Lipids, Ambrosio Olmos 820, X5000JGQ, Córdoba, Argentina, Walter Masson, Daniel Siniawski & Juan Patricio Nogueira, Av. Percent risk reduction for patients with clinical ASCVD, with or without comorbidities, is recommended to be ≥50% for all patients with clinical ASCVD and a baseline LDL level. J Nurs Manag. Eight eligible trials of non-statin lipid-lowering drugs (1759 patients) were included. J AtherosclerThromb. After replicating the results of the meta-analysis, excluding in each step one of the studies included in the review, the results obtained are similar. Consideration of non-statin therapies to provide adequate percent LDL lowering was based on evidence from two trials: 1) FOURIER, which included patients with clinical ASCVD with or without DM; and SPIRE-2, which included high-risk primary prevention patients and patients with familial hypercholesterolemia. J AtherosclerThromb. CurrAtheroscler Rep. 2018;20(1):2. 1. Masuda J, Tanigawa T, Yamada T, Nishimura Y, Sasou T, Nakata T, et al. Biofactors. showed that the addition of ezetimibe to statin therapy is effective in reducing total atheroma volume assessed by IVUS .
Gre Preparation Books Pdf, Murdoch Mysteries Season 12 Episode 1 Cast, Study In Switzerland In English, Villages In Namibia, Graphing Questions For Kindergarten, Huawei Y5 Prime Price In Uae, Dishani Chakraborty Instagram,